Randomised clinical trial: <i><scp>L</scp>actobacillus reuteri </i><scp>DSM</scp> 17938 vs. placebo in children with acute diarrhoea ‐ a double‐blind study

Francavilla, Ruggiero; Lionetti, Elena; Castellaneta, Stefania; Ciruzzi, F.; Indrio, Flavia; Masciale, A; Fontana, C.; Rosa, Mário Miguel; Cavallo, Luciano; Francavilla, A.

doi:10.1111/j.1365-2036.2012.05180.x

Cited by 97 publications

(95 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…One recent systematic review [28] identified two RCTs [5, 9], one of which [5] was first published as the abstract only, but is now published as a full paper. In the first study [9], 74 children aged 6 to 36 months with acute diarrhea were randomized to receive L. reuteri DSM 17938 or placebo for 7 days.…”

Section: Resultsmentioning

confidence: 99%

“…In the first study [9], 74 children aged 6 to 36 months with acute diarrhea were randomized to receive L. reuteri DSM 17938 or placebo for 7 days. Compared with the placebo group, in the L. reuteri group, there was a significant reduction in the duration of diarrhea (3.3 ± 2.1 vs. 2.1 ± 1.7 days, respectively; P < 0.03), the risk of watery diarrhea on day 2 (81 vs. 55 %, respectively, P < 0.02) and day 3 (73 vs. 46 %, respectively, P < 0.03), and the risk of relapse of diarrhea (42 vs. 15 %, respectively; P < 0.03).…”

Section: Resultsmentioning

confidence: 99%

See 1 more Smart Citation

The efficacy of Lactobacillus reuteri DSM 17938 in infants and children: a review of the current evidence

2014

View full text Add to dashboard Cite

We aimed to systematically evaluate evidence on the effectiveness of Lactobacillus reuteri DSM 17938 (L. reuteri) for treating and preventing diseases in infants and children. MEDLINE and the Cochrane Library were searched in December 2013, with no language restrictions, for relevant randomized controlled trials (RCTs) and meta-analyses. The search was updated in April 2014. One systematic review and 14 RCTs met the inclusion criteria. The use of L. reuteri may be considered in the management of acute gastroenteritis as an adjunct to rehydration. There is some evidence that L. reuteri is effective in reducing the incidence of diarrhea in children attending day care centers. There is no evidence of effectiveness of L. reuteri in preventing nosocomial diarrhea in children. The administration of L. reuteri is likely to reduce crying time in infants with infantile colic in exclusively or predominantly exclusively breast-fed infants, but not in formula-fed infants. More studies are needed. Preliminary data suggest that L. reuteri may be effective in the prevention of some functional gastrointestinal disorders, such as colic and regurgitation. This innovative approach needs further evaluation by an independent research team. Preliminary evidence provides a rationale for further assessing the efficacy of L. reuteri for treating functional constipation or functional abdominal pain. However, it is too soon to recommend the routine use of L. reuteri for these conditions. There are no safety concerns with regard to the use of L. reuteri in nonimmunocompromised subjects. There are also data to support the safety of using L. reuteri in preterm infants. Conclusion: Our results precisely define current evidence on the effects of the administration of L. reuteri DSM 17938 to the pediatric population.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

The efficacy of Lactobacillus reuteri DSM 17938 in infants and children: a review of the current evidence

2014

View full text Add to dashboard Cite

show abstract

“…In contrast, four trials in children and infants with enterovirulent bacterium-or rotavirus-and enterovirulent bacterium-induced diarrhea showed no decrease in the daily number of stools or duration of diarrhea after treatment with L rhamnosus GG (313)(314)(315)(316). Multicenter and other RCTs in children and infants have shown that the administration of L. reuteri DSM 17938 (L. reuteri ATCC 55730) shortened the duration of acute diarrhea and lowered the diarrhea relapse rate (282,(317)(318)(319).…”

Section: Therapeutic Effects Against Various Forms Of Acute Diarrheamentioning

confidence: 98%

Anti-Infective Activities of Lactobacillus Strains in the Human Intestinal Microbiota: from Probiotics to Gastrointestinal Anti-Infectious Biotherapeutic Agents

2014

View full text Add to dashboard Cite

SUMMARY A vast and diverse array of microbial species displaying great phylogenic, genomic, and metabolic diversity have colonized the gastrointestinal tract. Resident microbes play a beneficial role by regulating the intestinal immune system, stimulating the maturation of host tissues, and playing a variety of roles in nutrition and in host resistance to gastric and enteric bacterial pathogens. The mechanisms by which the resident microbial species combat gastrointestinal pathogens are complex and include competitive metabolic interactions and the production of antimicrobial molecules. The human intestinal microbiota is a source from which Lactobacillus probiotic strains have often been isolated. Only six probiotic Lactobacillus strains isolated from human intestinal microbiota, i.e., L. rhamnosus GG, L. casei Shirota YIT9029, L. casei DN-114 001, L. johnsonii NCC 533, L. acidophilus LB, and L. reuteri DSM 17938, have been well characterized with regard to their potential antimicrobial effects against the major gastric and enteric bacterial pathogens and rotavirus. In this review, we describe the current knowledge concerning the experimental antibacterial activities, including antibiotic-like and cell-regulating activities, and therapeutic effects demonstrated in well-conducted, placebo-controlled, randomized clinical trials of these probiotic Lactobacillus strains. What is known about the antimicrobial activities supported by the molecules secreted by such probiotic Lactobacillus strains suggests that they constitute a promising new source for the development of innovative anti-infectious agents that act luminally and intracellularly in the gastrointestinal tract.

show abstract

“…Lactobacillus reuteri is a microorganism often present, natural or added, in a variety of fermented foods, food supplements or infant formulas [1][2][3][4]. Reuterin (3-hydroxypropionaldehyde, 3-HPA) produced by some strains of Lb.…”

Section: Introductionmentioning

confidence: 99%

Glycerol and cobalamin metabolism in lactobacilli: relevance of the propanediol dehydrogenase pdh30

Langa

Arqués

Gaya

et al. 2015

Eur Food Res Technol

View full text Add to dashboard Cite

Randomised clinical trial: Lactobacillus reuteri DSM 17938 vs. placebo in children with acute diarrhoea ‐ a double‐blind study

Abstract: SUMMARY BackgroundProbiotics may be of help for the management of acute diarrhoea, however, the effect is strain specific and efficacy needs to be proven.

Cited by 97 publications

References 23 publications

The efficacy of Lactobacillus reuteri DSM 17938 in infants and children: a review of the current evidence

The efficacy of Lactobacillus reuteri DSM 17938 in infants and children: a review of the current evidence

Anti-Infective Activities of Lactobacillus Strains in the Human Intestinal Microbiota: from Probiotics to Gastrointestinal Anti-Infectious Biotherapeutic Agents

Glycerol and cobalamin metabolism in lactobacilli: relevance of the propanediol dehydrogenase pdh30

Contact Info

Product

Resources

About